Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. 

Research

Infection and Vaccines

Listed are The Kids Research Institute Australia research teams involved in our Infection and Vaccines Program. This program sits under the Early Environment research theme.

Research

Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.

Research

Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study

Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme

Research

Birth outcomes in Aboriginal mother–infant pairs from the Northern Territory, Australia, who received 23-valent polysaccharide pneumococcal vaccination during pregnancy

We found a numerically higher rate of preterm births among women who received 23vPPV in pregnancy compared to unvaccinated pregnant women

Research

FeBRILe3 Project: protocol for a prospective study and safety evaluation assessing Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months old

Assess the safety and impact of the introduction of a guideline recommending early discharge of infants with fever without source at low risk of serious bacterial infection

Research

Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children

Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia

Research

Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake

Amongst pregnant Australian women we aimed to ascertain vaccine information received, maternal immunisation uptake and attitudes and concerns regarding vaccines

Research

Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol

We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.

Research

Pertussis immunisation in infancy and atopic outcomes: A protocol for a population-based cohort study using linked administrative data

The burden of IgE-mediated food allergy in Australian born children is reported to be among the highest globally. This illness shares risk factors and frequently coexists with asthma, one of the most common noncommunicable diseases of childhood.